BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vermeulen R, Hosnijeh FS, Portengen L, Krogh V, Palli D, Panico S, Tumino R, Sacredote C, Purdue M, Lan Q. Circulating soluble CD30 and future risk of lymphoma; evidence from two prospective studies in the general population. Cancer Epidemiol Biomarkers Prev. 2011;20:1925-1927. [PMID: 21784955 DOI: 10.1158/1055-9965.epi-11-0396] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Makgoeng SB, Bolanos RS, Jeon CY, Weiss RE, Arah OA, Breen EC, Martínez-Maza O, Hussain SK. Markers of Immune Activation and Inflammation, and Non-Hodgkin Lymphoma: A Meta-Analysis of Prospective Studies. JNCI Cancer Spectr 2018;2:pky082. [PMID: 30873511 DOI: 10.1093/jncics/pky082] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
2 De Roos AJ, Mirick DK, Edlefsen KL, LaCroix AZ, Kopecky KJ, Madeleine MM, Magpantay L, Martínez-Maza O. Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma. Cancer Res 2012;72:4733-43. [PMID: 22846913 DOI: 10.1158/0008-5472.CAN-12-1639] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
3 Berger E, Delpierre C, Hosnijeh FS, Kelly-Irving M, Portengen L, Bergdahl IA, Johansson AS, Krogh V, Palli D, Panico S, Sacerdote C, Tumino R, Kyrtopoulos SA, Vineis P, Chadeau-Hyam M, Vermeulen R, Castagné R; EnviroGenoMarkers. Association between low-grade inflammation and Breast cancer and B-cell Myeloma and Non-Hodgkin Lymphoma: findings from two prospective cohorts. Sci Rep 2018;8:10805. [PMID: 30018397 DOI: 10.1038/s41598-018-29041-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
4 Purdue MP, Hofmann JN, Kemp TJ, Chaturvedi AK, Lan Q, Park JH, Pfeiffer RM, Hildesheim A, Pinto LA, Rothman N. A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma. Blood 2013;122:951-7. [PMID: 23814017 DOI: 10.1182/blood-2013-01-481077] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 5.3] [Reference Citation Analysis]
5 Solans M, Benavente Y, Saez M, Agudo A, Jakszyn P, Naudin S, Hosnijeh FS, Gunter M, Huybrechts I, Ferrari P, Besson C, Mahamat-Saleh Y, Boutron-Ruault MC, Kühn T, Kaaks R, Boeing H, Lasheras C, Sánchez MJ, Amiano P, Chirlaque MD, Ardanaz E, Schmidt JA, Vineis P, Riboli E, Trichopoulou A, Karakatsani A, Valanou E, Masala G, Agnoli C, Tumino R, Sacerdote C, Mattiello A, Skeie G, Weiderpass E, Jerkeman M, Dias JA, Späth F, Nilsson LM, Dahm CC, Overvad K, Petersen KEN, Tjønneland A, de Sanjose S, Vermeulen R, Nieters A, Casabonne D. Inflammatory potential of diet and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition. Eur J Nutr 2020;59:813-23. [PMID: 30903361 DOI: 10.1007/s00394-019-01947-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Purdue MP, Lan Q, Kemp TJ, Hildesheim A, Weinstein SJ, Hofmann JN, Virtamo J, Albanes D, Pinto LA, Rothman N. Elevated serum sCD23 and sCD30 up to two decades prior to diagnosis associated with increased risk of non-Hodgkin lymphoma. Leukemia 2015;29:1429-31. [PMID: 25567136 DOI: 10.1038/leu.2015.2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
7 Carrick DM, Chaturvedi AK, Shiels MS, Divi RL, Filipski KK, Hebert EF, Verma M, Hildesheim A. Using Immune Marker Panels to Evaluate the Role of Inflammation in Cancer: Summary of an NCI-sponsored Workshop. Cancer Epidemiol Biomarkers Prev 2015;24:1427-33. [PMID: 26108460 DOI: 10.1158/1055-9965.EPI-14-1419] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Purdue MP, Lan Q, Hoffman-Bolton J, Hildesheim A, Callahan CL, Strickland P, Visvanathan K, Rothman N. Circulating sCD27 and sCD30 in pre-diagnostic samples collected fifteen years apart and future non-Hodgkin lymphoma risk. Int J Cancer 2019;144:1780-5. [PMID: 30230539 DOI: 10.1002/ijc.31879] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Vermeulen R, Saberi Hosnijeh F, Bodinier B, Portengen L, Liquet B, Garrido-Manriquez J, Lokhorst H, Bergdahl IA, Kyrtopoulos SA, Johansson AS, Georgiadis P, Melin B, Palli D, Krogh V, Panico S, Sacerdote C, Tumino R, Vineis P, Castagné R, Chadeau-Hyam M, Botsivali M, Chatziioannou A, Valavanis I, Kleinjans JCS, de Kok TMCM, Keun HC, Athersuch TJ, Kelly R, Lenner P, Hallmans G, Stephanou EG, Myridakis A, Kogevinas M, Fazzo L, De Santis M, Comba P, Bendinelli B, Kiviranta H, Rantakokko P, Airaksinen R, Ruokojarvi P, Gilthorpe M, Fleming S, Fleming T, Tu YK, Lundh T, Chien KL, Chen WJ, Lee WC, Kate Hsiao C, Kuo PH, Hung H, Liao SF; EnviroGenoMarkers Consortium Consortium members. Pre-diagnostic blood immune markers, incidence and progression of B-cell lymphoma and multiple myeloma: Univariate and functionally informed multivariate analyses. Int J Cancer 2018;143:1335-47. [PMID: 29667176 DOI: 10.1002/ijc.31536] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
10 Epeldegui M, Martínez-Maza O. Immune Activation: Contribution to AIDS-Associated Non-Hodgkin Lymphoma. For Immunopathol Dis Therap 2015;6:79-90. [PMID: 28702272 DOI: 10.1615/ForumImmunDisTher.2016014177] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Levin LI, Breen EC, Birmann BM, Batista JL, Magpantay LI, Li Y, Ambinder RF, Mueller NE, Martínez-Maza O. Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis. Cancer Epidemiol Biomarkers Prev 2017;26:1114-23. [PMID: 28341757 DOI: 10.1158/1055-9965.EPI-16-1012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
12 Bassig BA, Shu XO, Koh WP, Gao YT, Purdue MP, Butler LM, Adams-Haduch J, Xiang YB, Kemp TJ, Wang R. Soluble levels of CD27 and CD30 are associated with risk of non-Hodgkin lymphoma in three Chinese prospective cohorts. Int J Cancer. 2015;137:2688-2695. [PMID: 26095604 DOI: 10.1002/ijc.29637] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
13 Epstein MM, Rosner B, Breen EC, Batista JL, Giovannucci EL, Magpantay L, Aster JC, Rodig SJ, Bertrand KA, Laden F, Martínez-Maza O, Birmann BM. Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies. Haematologica 2018;103:1679-87. [PMID: 29930163 DOI: 10.3324/haematol.2017.183236] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]